SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Rubius Therapeutics, Inc. – ‘10-K’ for 12/31/21 – ‘R15’

On:  Friday, 2/25/22, at 8:30am ET   ·   For:  12/31/21   ·   Accession #:  1558370-22-2057   ·   File #:  1-38586

Previous ‘10-K’:  ‘10-K’ on 2/23/21 for 12/31/20   ·   Next & Latest:  ‘10-K’ on 2/27/23 for 12/31/22   ·   15 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/25/22  Rubius Therapeutics, Inc.         10-K       12/31/21   74:10M                                    Toppan Merrill Bridge/FA

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.63M 
 2: EX-10.5     Material Contract                                   HTML     28K 
 3: EX-21.1     Subsidiaries List                                   HTML     22K 
 4: EX-23.1     Consent of Expert or Counsel                        HTML     21K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     23K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     23K 
14: R1          Document and Entity Information                     HTML     91K 
15: R2          Condensed Consolidated Balance Sheets               HTML    116K 
16: R3          Condensed Consolidated Balance Sheets               HTML     39K 
                (Parenthetical)                                                  
17: R4          Condensed Consolidated Statements of Operations     HTML     65K 
                and Comprehensive Loss                                           
18: R5          Condensed Consolidated Statements of Operations     HTML     24K 
                and Comprehensive Loss (Parenthetical)                           
19: R6          Condensed Consolidated Statements Stockholders      HTML     85K 
                Equity                                                           
20: R7          Condensed Consolidated Statements Stockholders      HTML     23K 
                Equity (Parenthetical)                                           
21: R8          Condensed Consolidated Statements of Cash Flows     HTML    118K 
22: R9          Nature of the Business and Basis of Presentation    HTML     31K 
23: R10         Summary of Significant Accounting Policies          HTML     64K 
24: R11         Investments and Fair Value of Financial Assets and  HTML     95K 
                Liabilities                                                      
25: R12         Property, Plant and Equipment, Net                  HTML     47K 
26: R13         Accrued Expenses and Other Current Liabilities      HTML     35K 
27: R14         Debt                                                HTML     53K 
28: R15         Equity                                              HTML     30K 
29: R16         Stock-Based Compensation                            HTML    105K 
30: R17         Income Taxes                                        HTML     93K 
31: R18         Commitments and Contingencies                       HTML     29K 
32: R19         Leases                                              HTML     84K 
33: R20         Net Loss per Share                                  HTML     54K 
34: R21         Summary of Significant Accounting Policies          HTML    109K 
                (Policies)                                                       
35: R22         Summary of Significant Accounting Policies          HTML     29K 
                (Tables)                                                         
36: R23         Investments and Fair Value of Financial Assets and  HTML     96K 
                Liabilities (Tables)                                             
37: R24         Property, Plant and Equipment, Net (Tables)         HTML     45K 
38: R25         Accrued Expenses and Other Current Liabilities      HTML     35K 
                (Tables)                                                         
39: R26         Debt (Tables)                                       HTML     47K 
40: R27         Stock-Based Compensation (Tables)                   HTML    103K 
41: R28         Income Taxes (Tables)                               HTML     90K 
42: R29         Leases (Tables)                                     HTML     81K 
43: R30         Net Loss per Share (Tables)                         HTML     55K 
44: R31         Nature of the Business and Basis of Presentation    HTML     58K 
                (Details)                                                        
45: R32         Summary of Significant Accounting Policies          HTML     37K 
                (Details)                                                        
46: R33         Summary of Significant Accounting Policies -        HTML     35K 
                Estimated useful life (Details)                                  
47: R34         Investments and Fair Value of Financial Assets and  HTML     61K 
                Liabilities (Details)                                            
48: R35         Property, Plant and Equipment, Net (Details)        HTML     56K 
49: R36         Accrued Expenses and Other Current Liabilities      HTML     34K 
                (Details)                                                        
50: R37         Debt (Details)                                      HTML     80K 
51: R38         Debt - Current and Non current (Details)            HTML     34K 
52: R39         Equity (Details)                                    HTML     52K 
53: R40         Stock-Based Compensation (Details)                  HTML     38K 
54: R41         Stock-Based Compensation - Granted to               HTML     30K 
                non-employees, prior to the adoption of ASU                      
                2018-07 (Details)                                                
55: R42         Stock-Based Compensation - Option activity          HTML     78K 
                (Details)                                                        
56: R43         Stock-Based Compensation - Performance based stock  HTML     51K 
                options (Details)                                                
57: R44         Stock-Based Compensation - Restricted Common Stock  HTML     57K 
                (Details)                                                        
58: R45         Stock-Based Compensation - Compensation expense     HTML     36K 
                (Details)                                                        
59: R46         Income Taxes (Details)                              HTML     46K 
60: R47         Income Taxes - U S federal statutory income tax     HTML     42K 
                rate (Details)                                                   
61: R48         Income Taxes - Net deferred tax assets (Details)    HTML     51K 
62: R49         Income Taxes - Valuation allowance for deferred     HTML     25K 
                tax assets (Details)                                             
63: R50         Commitments and Contingencies - Collaborative       HTML     29K 
                Arrangements and Non-collaborative Arrangement                   
                (Details)                                                        
64: R51         Commitments and Contingencies - Defined             HTML     29K 
                Contribution Plan (Details)                                      
65: R52         Leases (Details)                                    HTML     50K 
66: R53         Leases - Minimum lease payments (Details)           HTML     40K 
67: R54         Leases - Lease Portfolio (Details)                  HTML     45K 
68: R55         Net Loss per Share - Weighted Average Shares        HTML     39K 
                (Details)                                                        
69: R56         Net Loss per Share - Antidilutive Securities        HTML     29K 
                (Details)                                                        
72: XML         IDEA XML File -- Filing Summary                      XML    131K 
70: XML         XBRL Instance -- ruby-20211231x10k_htm               XML   1.60M 
71: EXCEL       IDEA Workbook of Financial Reports                  XLSX     91K 
10: EX-101.CAL  XBRL Calculations -- ruby-20211231_cal               XML    169K 
11: EX-101.DEF  XBRL Definitions -- ruby-20211231_def                XML    485K 
12: EX-101.LAB  XBRL Labels -- ruby-20211231_lab                     XML   1.21M 
13: EX-101.PRE  XBRL Presentations -- ruby-20211231_pre              XML    855K 
 9: EX-101.SCH  XBRL Schema -- ruby-20211231                         XSD    140K 
73: JSON        XBRL Instance as JSON Data -- MetaLinks              358±   527K 
74: ZIP         XBRL Zipped Folder -- 0001558370-22-002057-xbrl      Zip    998K

‘R15’   —   Equity

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v3.22.0.1
Equity
 12 Months Ended
Equity  
Equity

7. Equity

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.

On July 20, 2018, the Company filed a restated certificate of incorporation in the State of Delaware, which, among other things, restated the number of shares of all classes of stock that the Company has authority to issue to 160,000,000 shares, consisting of (i) 150,000,000 shares of common stock, $0.001 par value per share, and (ii) 10,000,000 shares of preferred stock, $0.001 par value per share. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company’s board of directors upon issuance. The shares of preferred stock are currently undesignated.

On August 1, 2019, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and SVB Leerink LLC (the “Sales Agents”), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $100.0 million through the Sales Agents. The Company’s registration statement on Form S-3 filed on August 1, 2019 was declared effective on August 21, 2019. The Sales Agents may sell common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Global Select Market or any other existing trade market for the common stock, in negotiated transactions at market prices prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law. The Sales Agents will be entitled to receive 3.0% of the gross sales price per share of common stock sold pursuant to the Distribution Agreement. As of December 31, 2021, no shares of common stock have been issued and sold pursuant to the Distribution Agreement.

On March 18, 2021, the Company completed the March 2021 Offering, pursuant to which it issued and sold 6,896,552 shares of common stock. The aggregate net proceeds received by the Company from the March 2021 Offering were $187.2 million, after deducting underwriting discounts and commissions and other offering costs.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/25/228-K
For Period end:12/31/215
3/18/21424B5,  8-K
8/21/19EFFECT
8/1/19S-3
7/20/184
 List all Filings 

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/27/23  Rubius Therapeutics, Inc.         10-K       12/31/22   77:7.2M
 6/08/22  Rubius Therapeutics, Inc.         S-3                    6:1M                                     Toppan Merrill/FA

13 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/09/21  Rubius Therapeutics, Inc.         10-Q        6/30/21   53:5.5M                                   Toppan Merrill Bridge/FA
 7/29/21  Rubius Therapeutics, Inc.         8-K:5,9     7/26/21   12:352K                                   Toppan Merrill/FA
 9/28/20  Rubius Therapeutics, Inc.         8-K:5,9     9/23/20   12:359K                                   Toppan Merrill/FA
 5/11/20  Rubius Therapeutics, Inc.         10-Q        3/31/20   53:5M                                     Toppan Merrill Bridge/FA
 3/12/20  Rubius Therapeutics, Inc.         10-K       12/31/19   86:13M                                    Toppan Merrill Bridge/FA
11/14/19  Rubius Therapeutics, Inc.         10-Q        9/30/19   67:7.4M                                   Toppan Merrill Bridge/FA
 8/01/19  Rubius Therapeutics, Inc.         S-3                    7:1.7M                                   Toppan Merrill-FA
 5/15/19  Rubius Therapeutics, Inc.         10-K/A     12/31/18    5:313K                                   Toppan Merrill Bridge/FA
12/21/18  Rubius Therapeutics, Inc.         8-K:1,2,9  12/21/18    2:749K                                   Toppan Merrill/FA
 7/23/18  Rubius Therapeutics, Inc.         8-K:5,8,9   7/17/18    3:223K                                   Toppan Merrill/FA
 7/09/18  Rubius Therapeutics, Inc.         S-1/A                 10:5.6M                                   Toppan Merrill-FA
 7/02/18  Rubius Therapeutics, Inc.         S-1/A                  7:1M                                     Toppan Merrill-FA
 6/22/18  Rubius Therapeutics, Inc.         S-1                   18:11M                                    Toppan Merrill-FA
↑Top
Filing Submission 0001558370-22-002057   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., May 17, 4:15:46.1pm ET